Anaplastic large cell lymphoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
** ALK+ 5-year survival 70-80% | ** ALK+ 5-year survival 70-80% | ||
** ALK- 5-year survival 30-40% | ** ALK- 5-year survival 30-40% | ||
ALK positive anaplastic large cell lymphoma affects primarily young (between 10 and 29 years), male patients<ref name="pmid11090048">{{cite journal| author=Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K et al.| title=CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. | journal=Blood | year= 2000 | volume= 96 | issue= 12 | pages= 3681-95 | pmid=11090048 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11090048 }} </ref> and accounts for 3% of all [[NHL]], 40% of all large cell lymphomas<ref>{{cite web|url=http://www.bloodjournal.org/content/93/8/2697?sso-checked=true|title=ALK+ Lymphoma: Clinico-Pathological Findings and Outcome}}</ref> and 10%-20% of childhood lymphomas.<ref>{{cite web|url=http://www.bloodjournal.org/content/93/8/2697?sso-checked=true|title=ALK+ Lymphoma: Clinico-Pathological Findings and Outcome}}</ref> | |||
According to a study on 1,320 cases of [[peripheral T-cell lymphomas]] and NK cell lymphomas between 1990 and 2002 in 22 different centers, ALK-Positive ALCL is the fifth most common type of peripheral T cell lymphoma (6.6% of total patients).<ref>{{cite web|url=http://jco.ascopubs.org/content/26/25/4124.full.pdf|title=International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes}}</ref> In the United states, ALK-Positive ALCL is the most frequent type of [[peripheral T-cell lymphoma]]. | |||
==References== | ==References== |
Revision as of 20:07, 9 October 2015
Anaplastic large cell lymphoma Microchapters |
Differentiating Anaplastic large cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Anaplastic large cell lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Anaplastic large cell lymphoma natural history, complications and prognosis |
FDA on Anaplastic large cell lymphoma natural history, complications and prognosis |
CDC on Anaplastic large cell lymphoma natural history, complications and prognosis |
Anaplastic large cell lymphoma natural history, complications and prognosis in the news |
Blogs on Anaplastic large cell lymphoma natural history, complications and prognosis |
Directions to Hospitals Treating Anaplastic large cell lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Prognosis
Those with ALK positivity have a better prognosis. It is possible that ALK-negative anaplastic large cell lymphomas represent other T-cell lymphomas that are morphologic mimics of ALCL in a final common pathway of disease progression. It is possible that existing systems of classification will be revised in the future to exclude such lymphomas from this specific diagnosis.
- Overall better prognosis than other "Aggressive Lymphomas"
- ALK+ 5-year survival 70-80%
- ALK- 5-year survival 30-40%
ALK positive anaplastic large cell lymphoma affects primarily young (between 10 and 29 years), male patients[1] and accounts for 3% of all NHL, 40% of all large cell lymphomas[2] and 10%-20% of childhood lymphomas.[3]
According to a study on 1,320 cases of peripheral T-cell lymphomas and NK cell lymphomas between 1990 and 2002 in 22 different centers, ALK-Positive ALCL is the fifth most common type of peripheral T cell lymphoma (6.6% of total patients).[4] In the United states, ALK-Positive ALCL is the most frequent type of peripheral T-cell lymphoma.
References
- ↑ Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K; et al. (2000). "CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features". Blood. 96 (12): 3681–95. PMID 11090048.
- ↑ "ALK+ Lymphoma: Clinico-Pathological Findings and Outcome".
- ↑ "ALK+ Lymphoma: Clinico-Pathological Findings and Outcome".
- ↑ "International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes" (PDF).